Fox Business News reported late last month on troubling news about the effects of a multiple sclerosis drug on patient brains. Our Chicago brain injury lawyers always attempt to share information about risks for these injuries, because we are well aware of the tremendous toll that brain trauma has on a patient.
The latest news comes from the Food and Drug Administration which has identified about 100 patients who have taken a drug known as Tysabri to treat multiple sclerosis and have subsequently developed a rare brain infection. The infection, known as progressive multifocal leukoencephalopathy (PML), involves the slow build up of white matter in the brain. It can develop in several places at once.
PML is a very serious infection. Those who identify the problem early enough can begin taking strong antiretroviral medications to treat the infection. However, the average patient with PML still passes away around 2 years after diagnosis.
Researchers have noted that the risk of developing PML is greatly increased once a patients has at least twenty four total Tysabri infusions to treat their MS. It is important for all patients to discuss these risks with their medical professional before agreeing to undergo any course of treatment. It is also imperative that the manufacturers of these drugs closely follow research patterns to discover the actually strength of association between the deadly brain infection and this pharmaceutical product.
Our Chicago brain injury attorneys at Levin & Perconti encourage multiple sclerosis patients to remain aware of the risks of their treatment options. Brain injuries are usually as serious as any other form of medical problem, and so risks should be minimized as much as possible. If you or a loved one has ever suffered the consequences of one of these traumatic injuries, be sure to seek appropriate legal help to learn about your rights.
See Our Related Blog Posts: